Figure 1
From: PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas
Clinical course and pathology of the cases with 1p19q codeletion. (a) Clinical course of the patients. ODG: oligodendroglioma, PCV: procarbazine, lomustine, and vincristine chemotherapy regimen (b) Representative H&E images from all the tumors. Scale bars indicate 250 µm (low magnification) and 50 µm (high magnification). (c) Genetic alterations detected in case 1 and hypermutator phenotype in case 2. The number of protein coding mutations detected in the primary tumor, relapsed tumor or both is represented in the figure. (d) New copy number alterations were detected in the relapsed tumors, more frequently in case 1. (e) Mainly focal intrachromosomal rearrangements accumulated in the relapsed tumors. Rearrangements are visualized with Circos plots. Rearrangements detected only in the primary or relapsed tumor are marked in red. (f) OncoPrint figure summarizing relevant alterations in the tumors. Both relapsed tumors harbored intragenic rearrangements in PTPRD and CNTNAP2. P: primary tumor, R: relapsed tumor. (g) Focal deletion at the transcription start site of PTPRD in both relapsed tumors. (h) Intragenic rearrangements detected in CNTNAP2 after tumor relapse. Deletion was present in case 1 and inversion in case 2. (i) The expression of both PTPRD and CNTNAP2 was strongly decreased after relapse. Bar plot showing the number of reads in normalized samples. P: primary, R: relapse.
